» Articles » PMID: 22566568

Complement-dependent Injury and Protection in a Murine Model of Acute Dextran Sulfate Sodium-induced Colitis

Overview
Journal J Immunol
Date 2012 May 9
PMID 22566568
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Complement plays a key role in the pathophysiology of many inflammatory diseases, and in this study, we investigated the role of complement in the pathogenesis of inflammatory bowel disease. Compared to wild-type mice, mice deficient in C3 or factor B were protected from acute dextran sulfate sodium (DSS)-induced colitis. C1q/mannose-binding lectin (MBL) double-deficient mice, however, exhibited more severe colitis than wild-type mice. When mice were allowed to recover after DSS treatment, all C1q/MBL(-/-) mice died by day 2 of recovery period, and, surprisingly, all C3(-/-) and factor B(-/-) mice died by day 5. Serum endotoxin levels were significantly increased in complement-deficient mice prior to death, particularly in C1q/MBL(-/-) mice, and antibiotic treatment prevented the lethal effect of DSS in all complement-deficient mice. In contrast to complement deficiency, targeted complement inhibition with either complement receptor 2 (CR2)-Crry (blocks all pathways at C3 activation) or CR2-factor H (blocks alternative pathway) was highly protective at treating established acute colitis. Endotoxin levels remained low in complement-inhibited mice, and complement inhibition also reduced inflammatory cytokines, leukocyte infiltration, and tissue injury while improving wound repair and mucosal healing. CR2-factor H provided more effective protection than CR2-Crry. Thus, complement has both pathogenic and protective roles in acute DSS-induced colitis, and whereas the alternative pathway appears to play a key role in tissue inflammation and injury, the classical/lectin pathway provides important protection in terms of host defense and wound repair. Targeted inhibition of the alternative pathway may represent a therapeutic modality for treating acute phases of inflammatory bowel disease.

Citing Articles

A Novel Probiotic Combination Ameliorates Crohn's Disease-Like Ileitis by Increasing Short-Chain Fatty Acid Production and Modulating Essential Adaptive Immune Pathways.

Di Martino L, Osme A, Ghannoum M, Cominelli F Inflamm Bowel Dis. 2023; 29(7):1105-1117.

PMID: 36715169 PMC: 10320237. DOI: 10.1093/ibd/izac284.


An Extremes of Phenotype Approach Confirms Significant Genetic Heterogeneity in Patients with Ulcerative Colitis.

Mortlock S, Lord A, Montgomery G, Zakrzewski M, Simms L, Krishnaprasad K J Crohns Colitis. 2022; 17(2):277-288.

PMID: 36111848 PMC: 10024548. DOI: 10.1093/ecco-jcc/jjac121.


C1q as a target molecule to treat human disease: What do mouse studies teach us?.

Schulz K, Trendelenburg M Front Immunol. 2022; 13:958273.

PMID: 35990646 PMC: 9385197. DOI: 10.3389/fimmu.2022.958273.


Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease Severity.

Guijarro L, Cano-Martinez D, Toledo-Lobo M, Ruiz-Llorente L, Chaparro M, Guerra I Biomedicines. 2022; 10(3).

PMID: 35327530 PMC: 8945466. DOI: 10.3390/biomedicines10030727.


The Dynamic Change of Gene-Regulated Networks in Cashmere Goat Skin with Seasonal Variation.

Hu S, Li C, Wu D, Huo H, Bai H, Wu J Biochem Genet. 2021; 60(2):527-542.

PMID: 34304316 DOI: 10.1007/s10528-021-10114-2.


References
1.
Stahl G, Xu Y, Hao L, Miller M, Buras J, Fung M . Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol. 2003; 162(2):449-55. PMC: 1851150. DOI: 10.1016/S0002-9440(10)63839-4. View

2.
Song H, He C, Knaak C, Guthridge J, Holers V, Tomlinson S . Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest. 2003; 111(12):1875-85. PMC: 161422. DOI: 10.1172/JCI17348. View

3.
Bak-Romaniszyn L, Szala A, Sokolowska A, Mierzwa G, Czerwionka-Szaflarska M, Swierzko A . Mannan-binding lectin deficiency in pediatric patients with inflammatory bowel disease. Scand J Gastroenterol. 2011; 46(10):1275-8. DOI: 10.3109/00365521.2011.594087. View

4.
Halstensen T, Mollnes T, Brandtzaeg P . Persistent complement activation in submucosal blood vessels of active inflammatory bowel disease: immunohistochemical evidence. Gastroenterology. 1989; 97(1):10-9. DOI: 10.1016/0016-5085(89)91409-1. View

5.
Woodruff T, Arumugam T, Shiels I, Reid R, Fairlie D, Taylor S . A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol. 2003; 171(10):5514-20. DOI: 10.4049/jimmunol.171.10.5514. View